Trial Profile
EXCELLENT (Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing) Registry.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 Oct 2015
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Sirolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
- Focus Therapeutic Use
- Acronyms EXCELLENT-REGISTRY
- 28 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 27 Aug 2009 New trial record